Please try another search
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for people with relapsed and refractory acute myeloid leukemia for bone marrow transplant; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Elihu H. Estey | - | - | Member of Clinical Advisory Board |
Sandesh C. Seth | 60 | 2012 | Chairman & CEO |
Sergio Giralt | - | 2014 | Member of Scientific Advisory Board |
David Colcher | - | 2018 | Members of Nuclear Medicine Clinical Advisory Board |
David A. Scheinberg | 68 | - | Member of Clinical Advisory Board |
Franklin Wong | - | 2018 | Members of Nuclear Medicine Clinical Advisory Board |
Hagop M. Kantarjian | - | - | Member of Clinical Advisory Board |
Jeffrey W. Chell | 70 | 2018 | Independent Director |
Johannes Czernin | - | 2018 | Members of Nuclear Medicine Clinical Advisory Board |
Alexander Perl | - | - | Member of Clinical Advisory Board |
Hillard M. Lazarus | - | 2014 | Member of Scientific Advisory Board |
C. David Nicholson | 69 | 2008 | Lead Independent Director |
Richard E. Champlin | - | 2014 | Member of Scientific Advisory Board |
Michael Yu | - | 2018 | Members of Nuclear Medicine Clinical Advisory Board |
Dan Pryma | - | 2018 | Members of Nuclear Medicine Clinical Advisory Board |
Ajit S. Shetty | 77 | 2017 | Independent Director |
John M. Pagel | - | - | Chairman of Scientific Advisory Board & Member of Clinical Advisory Board |
Richard L. Wahl | - | - | Member of Clinical Advisory Board |
Joseph G. Jurcic | - | - | Chairman of Clinical Advisory Board |
Richard M. Stone | - | 2017 | Member of Scientific Advisory Board |
M. Yair Levy | - | 2014 | Member of Scientific Advisory Board |
Richard I. Steinhart | 67 | 2013 | Independent Director |
Ghassan El-Haddad | - | 2018 | Members of Nuclear Medicine Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review